1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245–1255. PMID:
22353262.
Article
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011; 365:1118–1127. PMID:
21992124.
Article
3. Wang ZG, Lau W, Fu SY, Liu H, Pan ZY, Yang Y, et al. Anterior hepatic parenchymal transection for complete caudate lobectomy to treat liver cancer situated in or involving the paracaval portion of the caudate lobe. J Gastrointest Surg. 2015; 19:880–886. PMID:
25759077.
Article
4. Ahanatha Pillai S, Sathyanesan J, Perumal S, Ulagendra Perumal S, Lakshmanan A, Ramaswami S, et al. Isolated caudate lobe resection: technical challenges. Ann Gastroenterol. 2013; 26:150–155. PMID:
24714918.
5. Liu P, Qiu BA, Bai G, Bai HW, Xia NX, Yang YX, et al. Choice of approach for hepatectomy for hepatocellular carcinoma located in the caudate lobe: isolated or combined lobectomy? World J Gastroenterol. 2012; 18:3904–3909. PMID:
22876044.
Article
6. Chaib E, Ribeiro MA Jr, Souza YE, D'Albuquerque LA. Anterior hepatic transection for caudate lobectomy. Clinics (Sao Paulo). 2009; 64:1121–1125. PMID:
19936187.
Article
7. Ha TY, Hwang S, Lee YJ, Kim KH, Ko GY, Ii Gwon D, et al. Absence of benefit of transcatheter arterial chemoembolization (TACE) in patients with resectable solitary hepatocellular carcinoma. World J Surg. 2016; 40:1200–1210. PMID:
26666422.
Article
8. Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018; 18:416. PMID:
29653562.
Article
9. Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst. 2016; 108:djw133. PMID:
27377923.
Article
10. Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016; 34:160–167. PMID:
27730805.
Article
11. Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, et al. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl. 2017; 23:781–790. PMID:
28240808.
Article
12. Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018; DOI:
10.1001/jamaoncol.2017.5847. [in press].
13. Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017; 37:90–100.
Article
14. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. stereotactic radiotherapy for liver cancer. BMC Cancer. 2010; 10:475. PMID:
20813065.
Article
15. Wang JZ, Li XA, D'Souza WD, Stewart RD. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys. 2003; 57:543–552. PMID:
12957268.
Article
16. Zheng XK, Chen LH, Yan X, Wang HM. Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing. World J Gastroenterol. 2005; 11:1452–1456. PMID:
15770720.
Article
17. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011; 71:4366–4372. PMID:
21540236.
Article
18. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, Wu MS, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013; 62:606–615. PMID:
22773548.
Article
19. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010; 30:750–758. PMID:
20331505.
Article
20. Kang WH, Tak E, Hwang S, Song GW, Jwa E, Lee YJ, et al. Metformin-associated chemopreventive effects on recurrence after hepatic resection of hepatocellular carcinoma: from in vitro to a clinical study. Anticancer Res. 2018; 38:2399–2407. PMID:
29599368.
Article